Advertisement
Advertisement
NEUP
Neuphoria Therapeutics Inc. Common Stock
3.47
USDSponsored
-0.04
-1.14%
Oct 02, 15:57 UTC -4
Closed
After-Market
3.46
-0.01
-0.14%
NEUP Earnings Reports
Positive Surprise Ratio
NEUP beat 2 of 5 last estimates.
40%
Next Report
Date of Next Report
Nov 12, 2026
Estimate for Q1 27 (Revenue/ EPS)
--
/-$1.47
Implied change from Q4 26 (Revenue/ EPS)
-100.00%
/+54.74%
Implied change from Q1 26 (Revenue/ EPS)
--
/-66.67%
Neuphoria Therapeutics Inc. Common Stock earnings per share and revenue
On Sep 18, 2026, NEUP reported earnings of -0.95 USD per share (EPS) for Q4 26, missing the estimate of -0.57 USD, resulting in a -66.32% surprise. Revenue reached 1.17 million, compared to an expected --, with a 0.00% difference. The market reacted with a +0.27% price change (close before vs. close after earnings).
Looking ahead to Q1 27, 4 analysts forecast an EPS of -1.47 USD, with revenue projected to reach -- USD, implying an increase of 54.74% EPS, and decrease of -100.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
$0.00
Surprise
+99.70%
Palatin Technologies, Inc. Common Stock
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$1.21
Actual
-$1.11
Surprise
+8.42%
NeuroSense Therapeutics Ltd. Ordinary Shares
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$3.26
Actual
-$2.10
Surprise
+35.66%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
Nanobiotix S.A. - ADR
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.70
Surprise
-496.76%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$0.07
Surprise
+2,158.06%
Inventiva S.A. - ADR
Report Date
Sep 28, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.25
Surprise
+33.55%
Rezolute, Inc. Common Stock (NV)
Report Date
Sep 24, 2026 For Q4 26
Estimate
-$0.15
Actual
-$0.20
Surprise
-32.45%
FAQ
What were Neuphoria Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Neuphoria Therapeutics Inc. Common Stock reported EPS of -$0.95, missing estimates by -66.32%, and revenue of $1.17M, 0% as expectations.
How did the market react to Neuphoria Therapeutics Inc. Common Stock's Q4 2026 earnings?
The stock price moved up 0.27%, changed from $3.70 before the earnings release to $3.71 the day after.
When is Neuphoria Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 12, 2026.
What are the forecasts for Neuphoria Therapeutics Inc. Common Stock's next earnings report?
Based on 4
analysts, Neuphoria Therapeutics Inc. Common Stock is expected to report EPS of -$1.47 and revenue of -- for Q1 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.